Transfers R&D labs to Tanabe. The company also announced that it has acquired Tampa-based Thera Tec, manufacturer of nebulization systems marketed by Immunetech-subsidiary Dura Pharmaceuticals. The deals "will continue Immunetech's planned change from a research company to an operating pharmaceutical business," the company said. Immunetech retains all rights to its anti-allergy peptide Pentyde. NDA's for Pentyde Nasal Spray, Pentyde Injectable and Pentyde Ophthalmic are pending at FDA.
You may also be interested in...
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
The regulatory tools are for use in medical device development.
The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.